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EQ-5D Index and EQ-VAS; these are standardized, preference-based measures of 
health. Results were reported in descriptive and stratified analyses. Linear regres-
sion analyses were performed to determine the independent associations with 
the EQ-5D. Results: There were 297 matched physician and patient response 
forms. Mean patient age was 50 years and 64% were male. Mean EQ-5D Index was 
0.764 (SD= 0.283; range= -0.199-1.000). Mean EQ-VAS was 65.85 (SD= 21.00; 
range= 5-100). EQ-5D Index and EQ-VAS scores were significantly lower with wors-
ening disease severity. Among patients who had completed treatment, EQ-5D 
scores were higher for patients who achieved sustained virologic response (SVR) 
compared to those who did not (EQ-5D Index= 0.873 vs. 0.660, p-value= 0.0035). 
Regression models showed higher age and worsening disease severity were sig-
nificantly associated with lower EQ-5D Index and EQ-VAS scores. ConClusions: 
In a cross-sectional sample of HCV patients in France, utilities are linearly and 
significantly associated with disease progression, SVR, and age. This informa-
tion will be used to understand the benefits of treating patients and preventing 
disease progression.
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objeCtives: In 2012, the US Centers for Disease Control and Prevention published 
recommendations of one-time Hepatitis C virus (HCV) screening for adults born 
during 1945 through 1965. Evaluating U.S. HCV populations by birth segment may 
provide insights that could be increasingly relevant to payers and health care 
providers. Methods: Unique respondent data from the U.S. National Health and 
Wellness Survey from 2009-2012 were analyzed. Individuals aged ≥ 18 years who 
self-reported a Hepatitis C diagnosis were stratified into 3 cohorts based on birth 
year: pre-1946, 1946-1964, and post-1964. Characteristics, treatment rates, QOL 
(SF-12/36), and activity impairment (WPAI) were described. Results: Individuals 
born between 1946-1964 represented 64.6% of respondents with Hepatitis C (13.0% 
were older; 22.3% younger). The 1946-1964 cohort had a higher proportion of males 
than the younger population (65.3% vs. 59.3%, respectively; p< 0.05); 64.2% pre-1946 
were male. Insured status was higher (p< 0.05) in the older cohort (96.5%) versus 
the 1946-1964 (75.5%) or younger (70.2%) cohort. Reported current HCV treatment 
use was lower (p< 0.05) in the older cohort (3.2%) versus 1946-1964 (10.7%) or post-
1964 (21.4%). More than half in each cohort were treatment naïve (64.2% pre-
1946; 53.5% 1946-1964; 53.4% post-1964). A lower (p< 0.05) proportion (10.3%) of 
treatment naïve respondents born pre-1946 had a prior doctor recommendation 
for HCV therapy (versus 21.0% 1946-1964 or 21.1% post-1964). Mean percentage 
activity impairment was lower (p< 0.05) among pre-1946 cohort (34.4%) versus 
1946-1964 (45.3%) or post-1964 (45.1%). Mean Mental Summary Scores worsened 
from oldest to youngest cohorts (pre-1946= 50.6; 1946-1964= 43.8; post-1964= 39.5). 
Mean Physical Summary Scores were higher for the younger cohort (43.6) versus 
1946-1964 (40.2) or pre-1946 (41.2). ConClusions: In this Hepatitis C population 
analyzed by birth segment, individuals born 1946-1964 represented the largest 
segment of the population. Results suggest that differences by birth cohort may 
exist within this population regarding their characteristics, treatment rates, and 
patient-reported outcomes.
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objeCtives: No standardized methods to measure outcomes related to commu-
nity-acquired bacterial pneumonia (CABP) have been developed since release of 
the FDA Patient Reported Outcome (PRO) Guidance. The purpose of this literature 
review was to identify signs, symptoms, and measurement tools associated with 
patient experience of CABP. The results will be used to inform the development of 
a standardized measurement tool for CABP that is consistent with the FDA PRO 
Guidance. Methods: A search was conducted using OVID. MEDLINE (1946-present) 
and EMBASE (1988-2012) were searched using terms related to signs and symp-
toms of CABP and existing measurement and diagnostic tools. Results: The search 
identified 2158 abstracts. 940 were excluded based on pre-specified criteria. The 
remaining 1218 articles were scrutinized for eligibility resulting in 39 meeting the 
inclusion criteria. Thirty-four articles focusing on CABP signs and symptoms were 
identified in the literature. The most commonly reported symptoms were cough, 
chest pain, dyspnea, sputum production, and fatigue. The literature revealed that 
generic PRO instruments and an interviewer-administered measure including 10 
CABP symptoms have been used in CABP studies. Four CABP-specific instruments 
that assess patient-reported symptoms revealed notable methodological limitations 
and these were developed prior to the FDA PRO Guidance. ConClusions: There is 
a paucity of evidence on the most well-defined, reliable, reproducible, and feasible 
method for measuring efficacy outcomes in CABP trials. Establishing an appropri-
ate PRO endpoint for CABP is essential. Existing CABP-specific instruments were 
identified, however, they have methodological limitations, and were all developed 
prior to the FDA PRO Guidance. There is a need to develop a new PRO instrument in 
accordance with FDA guidance for PRO measures. The instrument should address 
limitations of current tools and accurately capture data on concepts and outcomes 
most important to patients.
initiated STRs; 1,681 (47%) initiated MTRs. Median persistence (95% confidence 
interval) was 36.5 (31.3, 38.9) months on STRs and 13.2 (11.9, 15.0) months on MTRs 
(Difference 23.3; P< 0.001).Within the subgroups persistent for the first 6 months, 
median persistence on MTRs was 26.1 (24.2, 28.3) and on STRs was 47.6 (41.2, 
54.3) months. Limiting the MTR analysis to those patients who had persistence ≥ 
6 months still fell short of the overall STR persistence (P< 0.001). ConClusions: 
Patients receiving an STR regimen had significantly longer median persistence, 
by almost two years, compared to those receiving MTRs. Even those patients who 
persisted on an MTR for the first 6 months experienced shorter overall persistence 
than those receiving an STR.
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objeCtives: The aims of this study were to (1) Estimate the relative strength of 
preferences for different attributes of Anti Retroviral Therapy (ART) using a stated 
preference discrete choice experiment (DCE) and (2) incorporate findings from quali-
tative research to supplement the data from the DCE. Methods: A European study 
in France, Italy, Spain, Germany and the UK was undertaken with an estimated1500 
PLWH designed to elicit patients’ strength of preference for different attributes 
of ARTs. This work presents the results from the UK and Germany. Participants 
were given a series of choice-style questions which presented hypothetical ARTs. 
Qualitative data were collected separately through individual interviews (n= 48) 
with PLWH recruited from HIV clinics in the UK and Germany. Results: In total, 
549 patients participated in the DCE (249 in UK) and (300 in Germany). The results 
showed that a rapid improvement in CD4 count and viral load were treatment attrib-
utes valued most highly by patients (UK: OR= 0.79; CI= 0.69-0.90; P< 0.001. Germany: 
OR= 0.79; CI= 0.71-0.87; P< 0.001). In addition, the absence of side effects such as diar-
rhoea was also valued highly (UK:OR= 0.57 CI= 0.51-0.65, p< 0.001. Germany: OR= 0.79, 
CI= 0.72-0.86; P< 0.001), as well as lower risk of long- term toxicities such as decline 
in renal function and an increase of cardiovascular risk (UK: OR= 0.30 CI= 0.25-
0.35, p< 0.001. Germany: OR= 0.55, CI= 0.48-0.63, p< 0.001). Other treatment attributes 
driving patient preference included reduction in treatment failure, absence of food 
restrictions with ART, and fewer drug-drug interactions (DDIs). The main differ-
ence between the German and UK results is that German patients did not value 
the absence of DDIs, the qualitative data suggests that they felt that these issues 
are being managed by their clinician. ConClusions: The DCE demonstrated that 
patients placed a great deal of importance on treatment efficacy as evidenced by 
the importance placed on these attributes.
PIN81
health state utIlIty values Of hIv INfeCted PatIeNts IN keNya
Patel A.1, van der Kop M.2, Lester R.1, Ojakaa D.3, Igunza P.3, Gichuki R.3, Mahal D.1, Marra C.1
1University of British Columbia, Vancouver, BC, Canada, 2Karolinska Institutet, Solna, Sweden, 
3African Medical and Research Foundation, Nairobi, Kenya
objeCtives: Health state utility values (HSUVs) in HIV are a key component of 
economic models that include Quality Adjusted Life years (QALY). There are limited 
HSUVs previously reported in HIV patients from Kenya. The objective of this study 
was to examine the HSUVs by severity of symptoms in an HIV infected popula-
tion. Methods: A Kiswahili translated SF-12 survey was administered to newly 
diagnosed HIV infected patients participating in a randomized, controlled trial in 
Nairobi, Kenya between April and October 2013. Patients were also asked if they were 
experiencing common symptoms of HIV (ie. fatigue, loss of appetite, depression or 
diarrhea) on a scale including no symptoms, mild, moderate or severe symptoms. 
SF-12 results were scored using Brazier’s SF6D utility algorithm. Mean HSUVs among 
patients reporting severe symptoms, mild/moderate symptoms or no symptoms 
were compared using ANOVA. Results: 135 respondents were included in the anal-
ysis with 7 observations removed due to missing data. HSUvs among asymptomatic 
HIV patients was 0.98 (SD= 0.04), among patients experiencing mild/moderate symp-
toms was 0.89 (SD= 0.12) and among patients experiencing severe symptoms was 
0.73 (SD= 0.16). ANOVA showed significant differences (p< 0.01) between group and 
a post-hoc Tukey test confirmed mean HSUVs were significantly different between 
those reporting severe symptoms and the other categories. ConClusions: This 
study measures HSUVs in a Kenyan cohort of HIV patients and confirms that sig-
nificant differences exist in quality of life between subgroups of these HIV infected 
patients. The utilities are inline with values measured in studies from other set-
tings. These HSUVs may be used to determine QALYs for use in health economic 
HIV research in Kenya.
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objeCtives: France has a high prevalence of chronic hepatitis C (HCV) and clinical 
impacts of the disease are well recognized. Despite this, information on utility 
and health-related quality of life (HRQoL) is limited. While it is generally accepted 
that HCV patients have reduced HRQoL, delineation of these values by disease 
stage and treatment outcome is not clear. These differences are important for 
determining the benefits of treating patients and preventing disease progression. 
This study assessed utility values of HCV patients in France by disease stage and 
treatment outcome. Methods: Physicians treating HCV patients in France were 
recruited to participate in the Hepatitis C Disease Specific Programme®. From 
October 2012 thru January 2013, physicians completed Patient Record Forms for 
10 consecutive patients presenting to their clinic. Information included patient 
demographics, disease stage, and treatment outcome. Patients completed the 
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high co-variability, when r ≥ 0.7, for regression analysis. The results of simple linear 
regression indicated that education status accounted for the greatest variance of the 
FACIT-TB total score, when the variance explained by all other variables in the model 
is controlled for (Beta = 0.325, P < 0.001), followed by financial status and smoking 
status. ConClusions: Our results confirmed that poor educational and financial 
statuses as well as being smokers are independent determinant of poor HRQL of 
PTB patients in Iraq.
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objeCtives: 1) To assess the overall Quality Of Life (QOL) of people living with HIV/
AIDS (PLWHA); 2) To compare the QOL in the six domains of health; and 3) To deter-
mine any association between age, gender, educational level and QOL. Methods: 
The study design is a descriptive cross sectional survey and the study population 
included all PLWHA who have enrolled into the Anti-Retroviral Therapy pharmacy of 
the University of Benin Teaching Hospital and were currently receiving their Highly 
Active Antiretroviral Therapy (HAART) for a period of at least six months. A trained 
interviewer administered a questionnaire that collects data on socio-demographics, 
clinicals and the items of World Health Organization Quality Of Life (WHOQOL) HIV-
bref from each participant. Means, standard deviations, and statistical tests for differ-
ences were performed. Results: A total of 360 respondents were surveyed. The mean 
age of the group was 38.58 years. 262 (72.8%) of respondents were females. The overall 
QOL of respondents was good with a mean score of (3.8 ±0.81). The QOL mean score 
were highest for the spirituality/religion/personal belief domain (16.03± 0.97) and 
lowest for the social relationships domain (11.38±1.01). The age of the respondents 
showed statistically significant differences (P< 0.05) in all domains of QOL except in 
the level of independence domain. Respondents in all the age groups had poor QOL 
in the social relationships domain. Females had statistically significant higher QOL 
mean scores in the physical, psychological and spirituality/ religion/ personal beliefs 
domains (P< 0.05) compared to males. The educational level of respondents showed 
statistically significant differences (P< 0.05) in physical, psychological, social relation-
ships and spirituality/ religion/ personal beliefs domains. Respondents with Tertiary 
education had higher QOL mean scores in the six domains of health. ConClusions: 
The study revealed good overall QOL among respondents. The mean QOL scores were 
highest in the spirituality/religion/personal beliefs domain and lowest in the social 
relationships.
PIN89
the assessmeNt Of PatIeNts’ health related QualIty Of lIfe durINg 
the COurse Of tuBerCulOsIs treatmeNt IN Baghdad, IraQ
Dujaili J.A.1, Syed Sulaiman S.A.1, Hassali M.A.2, Blebil A.Q.1, Awaisu A.3
1Universiti Sains Malaysia, Minden, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 
3Qatar University, Doha, Qatar
objeCtives: Quality of life (QoL) has become an accepted outcome measure in 
clinical research and advances have been made in assessing the impact of many 
diseases on QoL. The current study aimed to assess health related quality of life 
(HRQL) of subjects treated for active pulmonary tuberculosis (PTB) during the course 
of tuberculosis (TB) treatment. Methods: Consecutive PTB patients treated at 
Thoracic and Respiratory Disease Specialist Centre in Baghdad, Iraq were admin-
istered a validated TB-specific instrument. The Functional Assessment of Chronic 
Illness Therapy-Tuberculosis (FACIT-TB) total score and its subscales score at onset 
of treatment, after the intensive phase, and after completion of TB treatment were 
compared. Results: A total of 136 PTB patients were included in the analysis. After 
2 months, physical well-being (PWB), functional well-being (FWB), and FACIT-TB 
total scores were significantly increased (P < 0.01). However, there were no statis-
tical significant differences in social and economic well-being (SEWB), emotional 
well-being/living with TB (EWB/TB), and spiritual well-being (SpWB) subscales score. 
Furthermore, a significant improvement was observed in overall HRQL as indicated 
by FACIT-TB total score and all subscales except SEWB and SpWB at completion of TB 
treatment. ConClusions: The gradual increase in PWB, FWB and EWB/TB subscale 
scores over the course of TB treatment indicate the positive effect of medical therapy 
on patients’ QoL. However, interventions to offset social distress and dysfunction are 
important. Therefore individual’s perception toward this dimension of QoL should be 
addressed in future research.
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objeCtives: The transmission of C difficile infection (CDI) has recently changed, 
resulting in a five-fold increase in the incidence in the general population and an 
eight-fold increase among the elderly. We developed a simulation model to examine 
the dynamic relationship between three major subpopulations of CDI transmission: 
hospitals, long-term care facilities (LTCF), and communities, to evaluate treatment 
effectiveness and costs. Methods: A stochastic agent-tracking meta-population 
network model of CDI transmission has been developed. A framework for contagion 
dynamics between the three subpopulations (hospitals, LTCF and communities) was 
employed. We identified eight health states: susceptible, gastrointestinal exposure, 
colonized, diseased, clinically resolved colonized, relapsed, cleared, and deceased. 
Key parameters include: age-specific incidence rates, disease severity, hospital LOS, 
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objeCtives: We describe the process and progress of the Foundation for the NIH 
Biomarkers Consortium Project Team, a public-private partnership of government, 
academia, non-profit, and industry. The goal is development and qualification of 
a new community-acquired bacterial pneumonia (CABP) patient reported outcome 
(PRO) instrument incorporating reliable, well-defined, and relevant endpoints for 
patients in terms of how they feel and function in clinical trials of antibacterial drugs 
for CABP. Methods: We adhered to the FDA PRO Guidance for instrument develop-
ment and the 2010 FDA qualification process for drug development tools (DDTs). This 
guidance describes the process for DDTs intended for use in multiple drug develop-
ment programs, the goal of the current effort. Once qualified, drug developers can 
use DDTs for the qualified context in Investigational New Drug (IND) and New Drug 
Application (NDA)/Biological License Application (BLA) submissions without FDA 
reconsideration of the DDTs’ suitability. Results: The initial phase of instrument 
development included a literature review, a gap analysis, and interviews with six 
clinical experts. The most commonly reported symptoms identified by the literature 
review were cough, chest pain, dyspnea, sputum production, and fatigue. These find-
ings were used to inform the development of a study protocol and interview guide 
to elicit concepts from CABP patients. Following qualitative analysis of the interview 
transcripts, the team will draft a PRO instrument based on key concepts identified 
from CABP patients and experts. The draft PRO will be evaluated by an expert panel 
and refined through cognitive debriefing interviews with patients. ConClusions: A 
consortium-based approach will be useful and efficient in developing a new draft PRO 
measure for CABP, which incorporates published literature and data from qualitative 
interviews. The team is currently using a similar approach for development of a draft 
PRO for acute bacterial skin and skin structure infections (ABSSSI).
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objeCtives: Quality of life in HIV infected patients can be determined by a number of 
factors including severity of disease, social support and coping mechanisms. Common 
symptoms of HIV can be a key determinant of quality of life. The objective of this study 
was to examine the influence of symptoms associated with HIV disease on physi-
cal and mental of HIV infected patients in Kenya. Methods: A Kiswahili translated 
SF-12 survey was administered to newly diagnosed HIV infected patients participating 
in a randomized, controlled trial in Nairobi, Kenya between April and October 2013. 
Patients were also asked if they were experiencing common symptoms of HIV (i.e. 
fatigue, loss of appetite, depression or diarrhea) on a scale including no symptoms, 
mild, moderate or severe symptoms. SF-12 survey responses were scored to derive a 
physical component score (PCS) and mental component score (MCS). Linear regres-
sion was used to determine which symptoms were significantly associated with each 
score. Results: 135 respondents were included in the analysis with 7 observations 
removed due to missing data. Severe fatigue was associated with 15 point (p< 0.01) 
reduction in PCS while severe lack of appetite was associated with an 8.6 point (p< 0.01) 
reduction in PCS compared patients not experiencing these symptoms. Those expe-
riencing severe depression had 12.2 point (p< 0.01) lower MCS and those experiencing 
severe anxiety had 8.4 point (p< 0.01) lower MCS compared to those not experiencing 
these symptoms. ConClusions: This study is the first to examine which symptoms 
are associated with lower quality of life outcomes in a cohort of HIV infected patients 
in Kenya. The drivers of lower physical and mental may be valuable to inform clinical 
management and program planning efforts in HIV treatment and care.
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objeCtives: To assess the ability of the socio-demographic characteristics to 
predict health related quality of life (HRQL) of pulmonary tuberculosis (PTB) 
patients. Methods: The study was conducted between September 1st 2012 and July 
31st 2013, among consecutive PTB patients treated at Thoracic and Respiratory Disease 
Specialist Centre in Baghdad, Iraq. Functional Assessment of Chronic Illness Therapy-
Tuberculosis (FACIT-TB); a TB-specific HRQL instrument, along with a structured ques-
tionnaire to collect data on socio-demographic characteristics were administered. 
Standard multiple regression analysis was used to assess the ability of the socio-
demographic characteristics (age, marital status, education status, household size, 
breadwinner, financial status and smoking status) to predict HRQL of PTB patients as 
measured by FACIT-TB total score Results: Three hundred and five subjects were 
recruited over a period of 11 months. Participants ranged in age from 18 to 91 years, 
64.6% of them were male and 28.2% were illiterate. Furthermore, 50.8% of the patients 
in the sample were the major breadwinners for their families. The variables in the 
model explained 22.9% of the variance in the FACIT-TB total score, F (7,286) = 12.14, P 
< 0.001. Among the seven variables, education status, being the breadwinner, financial 
status, and smoking showed a significant bivariate relationship with the FACIT-TB 
total score. Correlations between these seven variables precluded the condition of 
